| scholarly article | Q13442814 |
| P50 | author | Branimir Ivan Sikic | Q28215761 |
| Martin S. Tallman | Q69035242 | ||
| Elisabeth Paietta | Q69071275 | ||
| Ranjana H. Advani | Q102148850 | ||
| P2093 | author name string | John M Bennett | |
| Jacob M Rowe | |||
| Sandra J Lee | |||
| Peter L Greenberg | |||
| David L Chin | |||
| Gordon Dewald | |||
| Bert Lum | |||
| Louis Letendre | |||
| Kathleen Dugan | |||
| P2860 | cites work | Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study | Q28139696 |
| International scoring system for evaluating prognosis in myelodysplastic syndromes | Q28305247 | ||
| Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine | Q33499728 | ||
| Acute myeloid leukemia | Q33741270 | ||
| Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance | Q34161314 | ||
| Population pharmacokinetics | Q39571946 | ||
| Multidrug resistance: clinical relevance in acute leukemia | Q40618951 | ||
| Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations | Q40935996 | ||
| Pharmacological considerations in the modulation of multidrug resistance | Q41078223 | ||
| Classical multidrug resistance in acute myeloid leukaemia | Q41541083 | ||
| Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. | Q41596669 | ||
| SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia | Q41639342 | ||
| Non-P-glycoprotein drug export mechanisms of multidrug resistance. | Q41668631 | ||
| Pharmacologic approaches to reversing multidrug resistance. | Q41668640 | ||
| Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. | Q43420831 | ||
| Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. | Q43543602 | ||
| Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype | Q43718996 | ||
| Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. | Q44083625 | ||
| Population pharmacokinetics of etoposide: application to therapeutic drug monitoring | Q44228680 | ||
| A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia | Q44280538 | ||
| Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity | Q45044199 | ||
| A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. | Q52301370 | ||
| Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study. | Q54104948 | ||
| Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). | Q54107205 | ||
| Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. | Q54125443 | ||
| Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. | Q54205188 | ||
| Clinical significance of P-glycoprotein in multidrug resistance malignancies. | Q54242231 | ||
| In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833 | Q54290439 | ||
| Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity | Q54291455 | ||
| Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A | Q54307469 | ||
| MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. | Q54321455 | ||
| Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia | Q58290404 | ||
| Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis | Q67894802 | ||
| Daunorubicin in patients with relapsed and refractory acute nonlymphoblastic leukemia previously treated with anthracycline | Q67919005 | ||
| Novel assay method for mitoxantrone in plasma, and its application in cancer patients | Q70261476 | ||
| Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer | Q71093076 | ||
| Modulation of multidrug resistance in de novo adult acute myeloid leukemia: variable efficacy of reverting agents in vitro. Eastern Cooperative Oncology Group | Q71698846 | ||
| Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells | Q72101168 | ||
| Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia | Q72229025 | ||
| A sensitive and simple high-performance liquid chromatographic method for the determination of mitoxantrone in plasma | Q72595918 | ||
| A sensitive and simple high-performance liquid chromatographic method for the determination of doxorubicin and its metabolites in plasma | Q72628675 | ||
| Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation | Q72681471 | ||
| P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival | Q72891082 | ||
| Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study | Q73292530 | ||
| Assay for etoposide in human serum using solid-phase extraction and high-performance liquid chromatography with fluorescence detection | Q74615606 | ||
| Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study | Q78039803 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| cytarabine | Q180983 | ||
| acute myeloid leukemia | Q264118 | ||
| myelodysplastic syndrome | Q954625 | ||
| etoposide | Q418817 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 1078-1086 | |
| P577 | publication date | 2004-03-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) | |
| P478 | volume | 22 |
| Q86953265 | A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells |
| Q92147359 | A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia |
| Q35953355 | A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia |
| Q45072417 | A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. |
| Q43193922 | ABC transporters in cancer: more than just drug efflux pumps. |
| Q35056738 | ABC transporters: unvalidated therapeutic targets in cancer and the CNS |
| Q35193725 | ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients |
| Q58798114 | ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward? |
| Q36893545 | ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia |
| Q47347882 | Acute Myeloid Leukaemia: New Targets and Therapies. |
| Q34327218 | Acute myeloid leukaemia in adults |
| Q36223607 | Advances in the molecular genetics of acute leukemia |
| Q37978341 | Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia? |
| Q37876908 | Amonafide: a potential role in treating acute myeloid leukemia |
| Q35664332 | Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial. |
| Q39071892 | Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience. |
| Q89805077 | CXCR4 Antagonists as Stem Cell Mobilizers and Therapy Sensitizers for Acute Myeloid Leukemia and Glioblastoma? |
| Q35038054 | Cancer stem cells and side population cells in breast cancer and metastasis. |
| Q33985549 | Challenges in treating older patients with acute myeloid leukemia |
| Q89994575 | Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study |
| Q33401218 | Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial |
| Q48215705 | Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience |
| Q35546759 | Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia |
| Q37392513 | Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study |
| Q52643794 | Development of liposomal pemetrexed for enhanced therapy against multidrug resistance mediated by ABCC5 in breast cancer. |
| Q37263146 | Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet |
| Q82507266 | Dismounting the MDR horse |
| Q28069761 | Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter? |
| Q52883093 | Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia. |
| Q33995372 | Drug delivery across the blood-brain barrier: why is it difficult? how to measure and improve it? |
| Q26824355 | Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation |
| Q35946969 | Drug resistance: still a daunting challenge to the successful treatment of AML. |
| Q33434711 | Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colonystimulating factor (CLAG) regime in patients with refractory or relapsed acute myeloid leukemia |
| Q52022309 | Expression dynamics of drug resistance genes, multidrug resistance 1 (MDR1) and lung resistance protein (LRP) during the evolution of overt leukemia in myelodysplastic syndromes. |
| Q46110606 | Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival |
| Q83906120 | Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia |
| Q36075226 | High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia |
| Q50512245 | High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). |
| Q45349631 | Homoharringtonine and granulocyte colony-stimulating factor priming for acute myeloid leukemia: is it ready for prime time? |
| Q42909895 | Increased ABCB1 Expression in TP-110-Resistant RPMI-8226 Cells |
| Q37813694 | Intrinsic resistance to chemotherapy in breast cancer |
| Q36416358 | Is targeted therapy feasible in acute myelogenous leukemia? |
| Q45051066 | Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse |
| Q90326700 | MDR1 in immunity: friend or foe? |
| Q37723847 | Myelodysplastic syndromes: clinical practice guidelines in oncology |
| Q33393647 | NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes |
| Q36284664 | New agents in the treatment of childhood leukemias and myelodysplastic syndromes |
| Q35930414 | Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis |
| Q33934534 | P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA |
| Q34124919 | P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808 |
| Q37627876 | Pharmacogenomics in acute myeloid leukemia. |
| Q36881996 | Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats |
| Q46898523 | Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Gr |
| Q37210470 | Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology |
| Q92593937 | Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial |
| Q36960756 | Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities |
| Q38055067 | Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? |
| Q38698037 | Semi-Quantitative Mass Spectrometry in AML Cells Identifies New Non-Genomic Targets of the EZH2 Methyltransferase. |
| Q33559358 | Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function |
| Q30497200 | Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia |
| Q52334917 | Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. |
| Q35918060 | Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukaemia |
| Q29616803 | Targeting multidrug resistance in cancer |
| Q33823577 | Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. |
| Q37683451 | Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside |
| Q37272565 | Targeting the leukemic stem cell: the Holy Grail of leukemia therapy |
| Q36788463 | Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor |
| Q28535342 | The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions |
| Q37289700 | The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms |
| Q90113477 | The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP |
| Q37941758 | The controversial role of ABC transporters in clinical oncology. |
| Q40397699 | The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children's Oncology Group |
| Q37414354 | Therapeutic potential of RNA interference in drug-resistant cancers |
| Q39051270 | Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP). |
| Q37352471 | Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). |
| Q47741553 | Treatment of relapsed/refractory acute myeloid leukaemia in adults |
| Q29617742 | Tumour stem cells and drug resistance |
| Q39342733 | Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape |
| Q36770191 | Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study |
| Q34360283 | Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999 |
| Q81625849 | [Cell cycle and apoptosis mechanisms implicated in intravesical chemotherapy resistances in superficial bladder cancer] |
| Q83989128 | [Risk-adapted therapy of acute myeloid leukemia] |
| Q39957937 | c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia |
| Q47375547 | microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview |
Search more.